Jefferies Financial Group Inc. JEF

Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within investment banking, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.

Con 22 acciones de JEF (USD 1.012,00) habrías recibido USD 35,20 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Can Jefferies' Expanded SMBC Partnership Bolster Its Growth in Japan?

  Jefferies Financial Group is launching a Japan-based joint venture with Sumitomo Mitsui Banking Corporation (SMBC) expected to begin operations in January 2027. SMBC has increased its equity stake in Jefferies to nearly 20%, becoming the largest shareholder. The JV will combine SMBC's domestic Japanese client relationships and equities capabilities with Jefferies' global investment banking network, targeting institutional equities and ECM opportunities. Early results show M&A and ECM market share for jointly covered sponsor clients increased more than fourfold since 2024.

  

• Zacks Investment Research 30 sept

  Jefferies' Q3 IB, Equities Offset Weak Asset Management & Fixed Income

  Jefferies Financial Group reported mixed Q3 fiscal 2026 results with record Investment Banking (up 17%) and Equities (up 29%) revenues reaching $1.33B and $626.2M respectively, offsetting significant weakness in Asset Management (down 52%) and Fixed Income (down 26%). Net revenues rose 9% YoY to $2.22B with net earnings increasing to $260.6M. The company's earnings growth sustainability depends on continued strength in deal-making and equities activity alongside improvement in weaker business segments.

  

• Zacks Investment Research 30 sept

  What Does Jefferies' Q3 Result Say About Wall Street's IB Recovery?

  Jefferies Financial Group reported record third-quarter investment banking revenues of $1.33B, up 17% year-over-year, with advisory revenues climbing 25% and equity underwriting surging 69%. The strong results suggest a healthy M&A backdrop and deal pipeline, though upcoming earnings from major banks are expected to show varied performance depending on their exposure to different banking segments.

  

• Zacks Investment Research 23 sept

  Gear Up for Jefferies (JEF) Q3 Earnings: Wall Street Estimates for Key Metrics

  Jefferies is expected to report Q3 earnings of $1.04 per share, down 1% year-over-year, with revenues forecast at $2.21 billion, up 8.1%. EPS estimates have been revised 8.1% higher over the last 30 days. Key metrics show mixed performance: Asset Management revenues declining 35.6%, while Investment Banking and Capital Markets revenues growing 12.7%. Equity underwriting is projected to surge 74%, though debt underwriting is expected to fall 29.9%. The stock has declined 9.7% in the past month and carries a Zacks Rank #3 (Hold) rating.

  

• GlobeNewswire Inc. 19 sept

  Kinzey Capital Management: Electra Sets Nasdaq IPO Terms

  Electra Therapeutics is pricing 21.7 million shares at $14-$16 each on Nasdaq under ticker ETRA, targeting up to $347 million to advance ipsoprubart through its SURPASS registration trial for secondary haemophagocytic lymphohistiocytosis. The offering values the clinical-stage antibody developer near $1 billion, with frontline data showing 100% overall survival at eight weeks versus historical 20-30% mortality rates.